S&P 500 Healthcare Sector SEC Filings — April 30, 2026

30-04-2026

Acacia Research Corporation (ACTG) filed its DEF 14A definitive proxy statement on April 30, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 23, 2026, at 1:00 p.m. ET. Stockholders of record as of April 28, 2026, will vote on electing five directors to serve until the 2027 annual meeting, ratifying Grant Thornton LLP as independent auditors for the fiscal year ending December 31, 2026, and approving named executive officer compensation on a non-binding advisory basis. The proxy highlights the Board's structure, including separation of Chairman (Gavin Molinelli) and CEO (Martin D. McNulty, Jr.) roles, with Maureen O’Connell as Lead Independent Director.

• ·Virtual Annual Meeting accessible at www.virtualshareholdermeeting.com/ACTG2026 with 16-digit control number required.
• ·Proxy materials and Form 10-K for fiscal year ended December 31, 2025, available at https://www.acaciaresearch.com/proxy-materials and www.proxyvote.com.
• ·Board committees: Audit (Chair: Isaac T. Kohlberg), Compensation (Chair: Michelle Felman), Nominating/Governance & Sustainability (Chair: Maureen O’Connell).
• ·Proxy solicitation assistance via Saratoga Proxy Consulting LLC at (888) 368-0379 (stockholders) or (212) 257-1311 (banks/brokers).

30-04-2026

Newmark Group, Inc. reported Q1 2026 total revenues of $846.5 million, up 27.2% YoY from $665.5 million, driven by 21.2% growth in Management Services, Servicing Fees, and Other to $344.0 million, 20.2% in Leasing to $250.0 million, and a record 45.5% in Capital Markets to $252.5 million. GAAP EPS surged 260% to $0.08 from ($0.05), Adjusted EPS rose 57.1% to $0.33, and Adjusted EBITDA increased 35.8% to $121.2 million; however, compensation expenses rose 29.3% to $515.4 million and non-compensation expenses increased 13.7% to $197.9 million, reflecting higher revenues and growth investments. The company raised its full-year outlook, amended its credit facility to $900 million, repurchased 10.4 million shares, and declared a $0.06 per share dividend.

• ·Servicing and Asset Management portfolio reached a record $222.1 billion, up 19.2% YoY.
• ·Net leverage stood at 1.0 times as of March 31, 2026.
• ·Quarterly dividend increased to $0.06 per share, payable May 29, 2026.
• ·Fully diluted weighted-average share count for Adjusted Earnings stable at 256.0 million, up 0.3% YoY.

30-04-2026

The Cigna Group reported strong Q1 2026 results with total revenues up 5% YoY to $68.5 billion and adjusted income from operations up 12% YoY to $2.1 billion ($7.79 per share), driven by growth in Evernorth Health Services and Cigna Healthcare, while raising full-year 2026 adjusted income outlook to at least $30.35 per share. However, Pharmacy Benefit Services adjusted income declined 28% YoY, Cigna Healthcare revenues fell 21% YoY due to the HCSC transaction (up 8% excluding it), and total customer relationships decreased 2% QoQ to 185.5 million. The adjusted SG&A expense ratio improved to 4.8% from 5.8% YoY, reflecting efficiency gains.

• ·Evernorth Health Services adjusted revenues up 9% YoY to $58.4 billion; adjusted income from operations pre-tax up 2% YoY to $1.47 billion (margin 2.5%).
• ·Debt-to-capitalization ratio 42.3% at Mar 31 2026 (down from 43.0% at Dec 31 2025).
• ·2026 outlook: Evernorth adjusted income from operations pre-tax at least $6.9 billion; Cigna Healthcare at least $4.525 billion; MCR 83.7% to 84.7%.
• ·Corporate adjusted loss from operations pre-tax $377 million in Q1 2026 (vs $411 million Q1 2025).

30-04-2026

SwitchPoint Financial Planning, LLC filed its 13F-HR report disclosing holdings as of March 31, 2026, across 102 positions with a total market value of $147,485,022. The portfolio is heavily weighted toward Dimensional ETF Trust funds (e.g., Emerging Markets Core, International Core Equity), Vanguard index funds and ETFs, and individual stocks including Alphabet Inc (Classes A and C), Apple Inc, Microsoft Corp, Amazon.com Inc, and Berkshire Hathaway. No period-over-period changes are provided in the filing.

• ·Filing date: April 30, 2026
• ·Report period end: March 31, 2026
• ·Business address: 2901 W Bluegrass Blvd, Suite 200-26, Lehi, UT 84043
• ·SEC file number: 028-24924

30-04-2026

Demars Financial Group, LLC filed its Form 13F-HR on April 30, 2026, disclosing equity holdings as of March 31, 2026, primarily consisting of sole discretionary positions in a diversified portfolio of individual stocks and ETFs. Key holdings include Apple Inc., Berkshire Hathaway Inc. Del Cl B, BWX Technologies Inc., Chubb Ltd., and various iShares and SPDR ETFs. No prior period comparisons or performance metrics are provided in the filing.

• ·Filing CIK: 0001723115
• ·State of Incorporation: WA
• ·Business Address: 420 N EVERGREEN RD, STE 300, SPOKANE VALLEY, WA 99216
• ·All positions reported as SOLE investment discretion

30-04-2026

CIMPRESS plc (CMPR) filed an 8-K on April 30, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing Q3 FY26 quarterly earnings. Details are contained in Exhibit 99.1 (q3_fy26quarterlyearnings.htm). No specific financial metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Filing Type: 8-K
• ·Items Reported: 2.02, 9.01
• ·Subcategory: Unregistered Securities Sale (noted but not detailed in content)
• ·Exhibit: EX-99.1 (Q3 FY26 Quarterly Earnings HTML)

30-04-2026

News Corporation disclosed updates provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, which authorizes up to $1 billion in aggregate repurchases of Class A and Class B common stock. The disclosures, attached as Exhibits 99.1 and 99.2, are made daily if transactions occur under the program. No specific repurchase volumes or amounts were detailed in the filing itself.

• ·Date of earliest event reported: April 29, 2026
• ·Filing Date: April 30, 2026
• ·Class A Common Stock trading symbol: NWSA (Nasdaq Global Select Market)
• ·Class B Common Stock trading symbol: NWS (Nasdaq Global Select Market)

30-04-2026

Canadian Pacific Kansas City Ltd (CP) reported Q1 2026 total revenues of $3,701 million, down 2% YoY from $3,795 million, with freight revenues declining 3% to $3,628 million as most segments decreased (e.g., Forest products -17%, Coal -12%) while Grain grew 11% to $871 million. Operating income fell 4% to $1,258 million and net income dropped 7% to $845 million (EPS $0.94 vs $0.98), though cash from operations was $976 million and the company ramped up share repurchases to $680 million from $347 million. Comprehensive income rose sharply to $1,398 million from $881 million, boosted by a $538 million foreign currency translation gain.

• ·Weighted-average basic shares decreased to 896.8 million from 933.2 million YoY due to repurchases.
• ·Dividends declared per share increased to $0.228 from $0.190.
• ·Additions to properties decreased to $664 million from $711 million.
• ·Long-term debt increased to $21,883 million as at March 31, 2026 from $19,948 million at Dec 31, 2025.

30-04-2026

X Financial's 20-F annual report discloses strong revenue growth of 22% YoY to RMB 5,871,782 thousand in 2024 and 30% to RMB 7,639,425 thousand in 2025, alongside total assets expanding 24% YoY to RMB 14,665,745 thousand by December 31, 2025. However, net income declined 5% YoY to RMB 1,464,553 thousand in 2025 following prior growth, cash and equivalents dropped 18% in 2024 before flattening in 2025, and regulatory risks include potential fines up to RMB 50 million or 5% of revenues under China's Personal Information Protection Law. Shareholder returns remained robust with dividends increasing to US$0.28 per ADS and share repurchases totaling approximately US$127.4 million in 2024-2025.

• ·Investments in Consolidated VIEs, Trusts and Partnerships and subsidiaries increased to RMB 7,503,918 thousand as of Dec 31, 2025.
• ·Loan receivable from Xiaoying Credit Loans and other loans, net (consolidated): RMB 5,298,631 thousand as of Dec 31, 2025.
• ·Capital repatriation restrictions may limit dividends from PRC subsidiaries and VIEs to offshore holding company.

30-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 30, 2026, announcing the issuance of a press release titled 'AITX's RAD Enters Hospitality Sector with First Major Hotel Brand Order.' This represents the company's expansion into the hospitality sector via its RAD product with its inaugural major order from a hotel brand. No financial details or performance metrics were disclosed.

30-04-2026

Viewbix Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, changing its name to Quantum X Labs Inc., effective 12:01 a.m. Eastern Time on April 30, 2026. The amendment was approved by the Board of Directors and executed by CEO Amihay Hadad on April 29, 2026. The company was originally incorporated as Infergene Company on August 16, 1985.

• ·Originally incorporated under the name Infergene Company on August 16, 1985, in Delaware.

30-04-2026

ACRES Commercial Realty Corp. (ACR) announced a definitive all-stock merger agreement to acquire ACRES Capital Corp. (ACC) and its subsidiary ACRES Capital, LLC, internalizing management and expanding assets under management from $2.2B to an anticipated $4.7B, with ~7.5M ACR shares issued (net increase of 6.3M shares after consolidation). The transaction, approved by a Special Committee of independent directors, is expected to align interests (management to own >45% equity), add third-party fee income, and be accretive to earnings available for distribution while supporting dividend stability. However, it remains subject to stockholder approval, customary closing conditions, and carries risks such as failure to close, transition challenges, litigation, or impacts on dividends and retention.

• ·Merger consideration priced at ACR’s fully diluted book value per share as of December 31, 2025
• ·Expected closing in third quarter of 2026
• ·ACR Special Committee advised by BTIG, LLC (financial), Hunton Andrews Kurth LLP (legal), and Meridian Compensation Partners, LLC (compensation)

30-04-2026

Cat Financial reported Q1 2026 revenues of $947 million, up 10% from $860 million in Q1 2025, driven by higher average earning assets, with profit rising 11% to $144 million and retail new business volume increasing 8% to $3.19 billion. However, net write-offs increased to $29 million from $20 million, and total assets were essentially flat at $38,163 million compared to $38,313 million at year-end 2025. Past dues improved to 1.39% from 1.58%, while the allowance for credit losses remained stable at 0.86% of receivables.

• ·Higher general, operating and administrative expenses partially offset profit before tax growth by $22 million.
• ·Favorable impact from higher average earning assets contributed $40 million to profit before tax increase.

30-04-2026

International Paper reported first quarter 2026 net sales of $5.97 billion, up approximately 13% YoY from $5.26 billion, with earnings from continuing operations of $76 million versus a $124 million loss in Q1 2025, and strong cash from operations of $611 million versus negative $288 million YoY. However, adjusted EBITDA declined slightly to $677 million from $689 million YoY, Packaging Solutions North America operating profit fell 22% QoQ to $248 million from $319 million despite YoY gains, and Packaging Solutions EMEA reported a $51 million operating loss versus a $46 million profit YoY. The company received $1.1 billion net proceeds from the Global Cellulose Fibers sale, paying down $660 million in debt, amid a tougher macro environment including inflation and winter storms.

• ·Q2 2026 Adjusted EBITDA guidance: $520-$570 million
• ·Full-year 2026 Adjusted EBITDA guidance: $3.20-$3.50 billion
• ·Net special items Q1 2026: $19 million after-tax charge
• ·10-Q filing planned for May 5, 2026
• ·PS EMEA net sales Q1 2026: $2,323 million, up significantly YoY from $1,550 million

30-04-2026

For the three months ended March 31, 2026, StageWise Strategies Corp. reported revenue of $25,249, up 68% YoY from $15,000, with operating expenses declining 38% to $16,693, resulting in net income of $8,556 versus a prior-year loss of $11,980. However, for the six months ended March 31, 2026, revenue fell 36% YoY to $44,467 from $69,690, leading to a net loss of $5,687 compared to a profit of $15,720, while cash and cash equivalents depleted to $0 from $4,573 at period start.

• ·1,000,000 common shares cancelled during six months ended March 31, 2026.
• ·Intangible assets decreased to $131,987 from $152,216 as of September 30, 2025.
• ·Net cash used in operating activities: $7,206 for six months ended March 31, 2026 (improved from $17,138 prior year).
• ·Loan from related parties repaid by $11,779 during six months ended March 31, 2026.

30-04-2026

Merck & Co., Inc. reported first-quarter 2026 worldwide sales of $16.3 billion, up 5% YoY (3% ex-FX), driven by strong growth in KEYTRUDA ($8.0 billion, +12%), WINREVAIR ($525 million, +88%), and Animal Health ($1.8 billion, +13%), but offset by declines including GARDASIL (-19%), JANUVIA/JANUMET (-28%), ROTATEQ (-10%), VAXNEUVANCE (-12%), and LAGEVRIO (-73%). GAAP and non-GAAP loss per share were $1.72 and $1.28, respectively, compared to profits of $2.01 and $2.22 in Q1 2025, primarily due to a $3.62 per share ($9.0 billion) charge for the Cidara Therapeutics acquisition. The company narrowed and raised its full-year 2026 guidance to worldwide sales of $65.8-$67.0 billion and non-GAAP EPS of $5.04-$5.16, excluding the pending Terns Pharmaceuticals acquisition expected to close in May with a $5.8 billion charge.

• ·U.S. FDA approval for IDVYNSO, a once-daily oral treatment for certain adults with virologically suppressed HIV-1.
• ·Presented new data from cardio-pulmonary pipeline at ACC.26, including positive Phase 3 CORALreef AddOn Trial results.
• ·Agreement to acquire Terns Pharmaceuticals, Inc. to expand hematology pipeline with TERN-701 for chronic myeloid leukemia; expected to close in May 2026.
• ·OHTUVAYRE sales of $131 million from October 2025 Verona Pharma acquisition.
• ·Koselugo alliance revenue $161 million in Q1 2026 vs. $44 million in Q1 2025 due to collaboration amendment with AstraZeneca.

30-04-2026

Baxter International Inc. reported first-quarter 2026 sales from continuing operations of $2.7 billion, increasing 3% on a reported basis but declining 1% organically, with U.S. sales down 4% to $1.44 billion while international sales rose 12% reported (3% organic) to $1.27 billion. Segment results were mixed: Medical Products & Therapies sales of $1.3 billion declined 2% organically, Healthcare Systems & Technologies at $705 million were flat reported (down 2% organic), and Pharmaceuticals grew 7% reported (1% organic) to $621 million; adjusted diluted EPS from continuing operations was $0.36, down 35% YoY. The company reiterated its full-year 2026 outlook for flat to 1% reported sales growth, approximately flat organic growth, and adjusted EPS of $1.85 to $2.05.

• ·GAAP diluted EPS (loss) from continuing operations of ($0.03); net income (loss) from continuing operations ($17) million.
• ·Full-year 2026 outlook: reported sales growth flat to 1%, organic sales growth approximately flat, adjusted EPS $1.85 to $2.05.
• ·Kidney Care business divested in January 2025, reported as discontinued operations.
• ·Upcoming investor events: BofA Securities 2026 Health Care Conference (May 13, 2026), Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026).

30-04-2026

Eli Lilly reported Q1 2026 revenue of $19.8 billion, up 56% YoY from $12.7 billion, driven by 65% volume growth primarily from Mounjaro ($8.7B, +125%) and Zepbound ($4.2B, +80%), though partially offset by 13% lower realized prices overall. Reported EPS rose 170% to $8.26 and non-GAAP EPS 156% to $8.55, with raised FY2026 guidance to $82.0-85.0 billion revenue (from $80-83B prior) and $35.50-37.00 non-GAAP EPS; however, gross margin as % of revenue declined 0.6pp to 81.9%, R&D expenses increased 28% to $3.5 billion, and IPR&D charges were $584 million versus $1.6 billion prior year. Key highlights include FDA approval of Foundayo and acquisitions of Orna Therapeutics, Centessa, Kelonia, and Ajax Therapeutics.

• ·U.S. revenue increased 43% to $12.1 billion, outside U.S. +81% to $7.7 billion but with 25% lower realized prices ex-U.S.
• ·Acquired IPR&D charges $584M in Q1 2026 vs. $1.6B in Q1 2025 (primarily Scorpion Therapeutics' STX-478).
• ·Asset impairment, restructuring and other special charges $279M in Q1 2026 (litigation-related).
• ·Jardiance revenue outside U.S. included one-time benefits of $250M in Q1 2026 vs. $370M in Q1 2025.
• ·Planned Investment Community Meeting for December 7, 2026.
• ·U.S. FDA approval of Foundayo for adults with obesity or overweight with weight-related medical problems.

30-04-2026

American Financial Group reported Q1 2026 net earnings of $191 million ($2.29 per share), up from $154 million ($1.84 per share) YoY, with core net operating earnings of $206 million ($2.47 per share), a 36% increase driven by 66% higher Specialty P&C underwriting profit of $156 million. However, results were partially offset by $15 million after-tax non-core realized losses and lower alternative investment returns of -0.4% annualized versus 1.8% YoY. The company returned $259 million to shareholders and expects a $125 million pretax core gain from the sale of Charleston Harbor Resort & Marina, closing in Q2 or Q3 2026.

• ·Specialty P&C combined ratio improved to 90.3% from 94.0% YoY, with cat losses at 2.2 points vs 4.5 points.
• ·Book value per share $56.30 at March 31, 2026; excluding AOCI $57.83 (down from $58.38 at end-2025).
• ·After-tax non-core net realized losses $15 million ($0.18 per share) in Q1 2026 vs gains of $2 million ($0.03 per share) in Q1 2025.
• ·Q1 2026 gross/net written premiums up 11%/6% in Property & Transportation Group; 2%/2% in Specialty Casualty; 6%/1% in Specialty Financial.
• ·Average renewal pricing up ~5% excluding workers' comp, ~3% including.

30-04-2026

Unicycive Therapeutics, Inc. filed Definitive Additional Materials (DEFA14A) on April 30, 2026, providing notice of proxy materials availability for its 2026 Annual Meeting on June 19, 2026. Key proposals include the election of three director nominees (Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. S. Kenkare-Mitra) and ratification of Grassi & Co., CPAs, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with the board recommending 'For' all items. No financial results or performance metrics are disclosed in this filing.

• ·Annual Meeting location: 1975 W. El Camino Real, Suite 204, Mountain View, CA 94040 at 10:00 AM PDT
• ·Voting deadline: June 18, 2026, 11:59 PM ET
• ·Proxy materials request deadline: June 07, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com

30-04-2026

OneWater Marine Inc. reported fiscal Q2 2026 revenue of $442.3 million, down 8.5% YoY from $483.5 million, with new boat sales declining 12.1% and service/parts/other down 10.7%, though pre-owned boat revenue rose 5.2%. Gross profit margin expanded 110 bps to 23.9% due to favorable mix and margin discipline, but GAAP net loss widened to $12.9 million ($(0.78) per share) from $0.4 million, with Adjusted EBITDA slipping to $16.3 million from $17.9 million. The company repaid $56.6 million in debt using proceeds from the OBCI sale, reducing inventory to $551.4 million and adjusted net debt leverage to 4.1x.

• ·Total liquidity as of March 31, 2026: $72.9 million.
• ·FY2026 guidance: Dealership same-store sales flat YoY; Adjusted diluted EPS $0.20 to $0.70.
• ·Trailing twelve-month Adjusted EBITDA as of March 31, 2026: $70.3 million.
• ·Six months ended March 31, 2026 total revenue: $822.9 million (down from $859.3 million YoY).

30-04-2026

Bridgewater Bancshares Inc reported robust YoY growth for Q1 2026, with net income rising 80.7% to $17,406 (thousands) from $9,633, net interest income up 21.3% to $36,647 (thousands), and EPS basic at $0.59 versus $0.31, fueled by higher loan interest income (+14.7%) and lower interest expense (-6.1%). However, the securities portfolio declined sharply 27% QoQ to $566,565 (thousands), total assets fell 1.3% QoQ to $5,335,396 (thousands), deposits dipped slightly 0.3% QoQ, and noninterest expenses increased 22.2% YoY to $22,170 (thousands). Provision for credit losses improved to $1,200 (thousands) from $1,500 (thousands) YoY.

• ·Net gain on sales of available for sale securities: $7,251 (thousands) in Q1 2026 vs $1 (thousands) in Q1 2025
• ·FHLB Advances: $336,000 (thousands) at March 31, 2026 vs $399,500 (thousands) at Dec 31, 2025
• ·Allowance for Credit Losses: $57,277 (thousands) at March 31, 2026 vs $56,443 (thousands) at Dec 31, 2025
• ·Cash and Cash Equivalents increased $98,643 (thousands) in Q1 2026
• ·Proceeds from sales of securities: $208,501 (thousands) in Q1 2026

30-04-2026

Aptose Biosciences Inc. filed an 8-K on April 30, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing the issuance of a press release attached as Exhibit 99.1. The press release is furnished but not deemed 'filed' under the Exchange Act. The filing was signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer.

30-04-2026

Riverview Bancorp reported fiscal Q4 2026 net interest income of $10.2 million, up from $9.2 million YoY, with net interest margin expanding 27 basis points to 2.92%; however, GAAP net loss was $8.0 million or $0.39 per diluted share due to a $11.4 million pre-tax loss from the strategic sale of $149.3 million in lower-yielding securities, while non-GAAP net income was $656,000 or $0.03 per share. Loans grew $7.4 million QoQ to $1.08 billion and $30.0 million YoY, deposits increased $20.7 million QoQ to $1.25 billion, but non-interest income excluding optimization declined to $3.3 million from $3.7 million YoY and non-interest expense rose modestly to $11.5 million. The balance sheet optimization is expected to add 25 basis points to NIM and $0.13 to annual EPS once fully realized.

• ·Non-performing assets at 0.53% of total assets and 0.71% of total loans.
• ·Loan pipeline $56.4 million at March 31, 2026, down from $77.2 million in Q3.
• ·Shareholders’ equity $145.6 million at March 31, 2026, down from $164.2 million in Q3.
• ·Tangible book value per share $5.76.
• ·Cash dividend of $0.02 per share paid April 24, 2026.
• ·$4.0 million stock repurchase plan adopted January 22, 2026.

30-04-2026

Apollo Commercial Real Estate Finance, Inc. (ARI) filed a 10-K/A on April 30, 2026, amending its annual report by incorporating various exhibits by reference, including an Asset Purchase and Sale Agreement with Athene Holding Ltd. dated January 27, 2026, and an Amended and Restated Management Agreement dated April 24, 2026. Security ownership disclosures indicate directors and executives collectively hold 689,419 common shares, with major holders BlackRock, Inc. (20,790,277 shares, 15.6%), Qatar Investment Authority (10,493,529 shares, 7.9%), and Vanguard entities owning significant stakes; no changes in ownership percentages are highlighted. Executive compensation details for CFO Anastasia Mironova show stable but modest allocable expenses, including $39,031 for taxes and $22,044 for benefits in 2025.

• ·Asset Purchase and Sale Agreement dated January 27, 2026, with Athene Holding Ltd.
• ·Letter Agreements dated January 27, 2026, with ACREFI Operating, LLC, ACREFI Management, LLC, and Apollo Management Holdings, L.P.
• ·New certifications filed as Exhibit 31.3* (Principal Executive Officer) and 31.4* (Principal Financial Officer) pursuant to Section 302 of Sarbanes-Oxley.

30-04-2026

State of New Jersey Common Pension Fund A filed its 13F-HR holdings report as of March 31, 2026, on April 30, 2026, disclosing sole ownership positions in three securities. Key holdings include Blue Owl Capital Corporation with a fair market value of $168,818,435 thousand (15,263,873 shares), Blue Owl Capital Inc Class A with $32,464,180 thousand (3,555,770 shares), and TPG RE Fin Tr Inc with $24,594,846 thousand (3,149,148 shares). The filing provides a snapshot of these positions with no prior period data or changes indicated.

• ·Filing CIK: 0001483262
• ·Conformed period end: March 31, 2026
• ·SEC file number: 028-13665

30-04-2026

State of New Jersey Common Pension Fund E filed its 13F-HR report on April 30, 2026, for the quarter ended March 31, 2026, disclosing a holding of 6,270,099 shares of Blue Owl Technology Fin Corp common stock with sole voting power. The fair market value of this position was reported as $77,686,527. No other holdings or changes were detailed in the provided filing content.

• ·CUSIP for holding: 095924106
• ·Filer CIK: 0001483260
• ·SEC File Number: 028-13669

30-04-2026

The New Jersey Better Educational Savings Trust filed its 13F-HR report for the period ending March 31, 2026, disclosing total holdings valued at $60,909,062 across four positions, all held on a sole basis. Largest holdings by value are iShares USD Investment Grade ETF at $26,009,113 (507,693 shares) and Vanguard Total Bond Market ETF at $26,112,302 (354,594 shares), with smaller positions in iShares Core S&P 500 ETF ($4,392,184; 6,724 shares) and SPDR Series Trust State Street SPD ($4,395,463; 57,427 shares). No prior period data is provided for comparison.

• ·Filing filed on April 30, 2026, for quarter ended March 31, 2026
• ·All positions held with sole voting and sharing authority

30-04-2026

This 10-K/A filing discloses beneficial ownership as of April 30, 2026, with Ampersand 2018 Limited Partnership holding 13,861,386 shares or 50.0% of outstanding shares, and 1315 Capital II, L.P. holding 9,405,941 shares or 34.0%. Executive officers and directors as a group (6 persons) beneficially own 257,984 shares, representing less than 1%. Together, the two 5% holders control 84% of the company.

• ·Filing is an amendment (10-K/A) dated April 30, 2026

30-04-2026

Esquire Financial Holdings, Inc. filed a DEF 14A proxy statement for its Annual Meeting on May 28, 2026, proposing the election of four directors (three for three-year terms and one for a two-year term), ratification of Crowe LLP as independent auditors for the year ending December 31, 2026, and an advisory 'Say-on-Pay' vote on executive compensation. As of the record date of March 26, 2026, there were 8,637,034 shares of common stock outstanding, with directors and executive officers beneficially owning 1,207,556 shares (13.9%) in aggregate. Major 5% shareholders include Mawer Investment Management Ltd. (779,889 shares, 9.0%) and BlackRock, Inc. (525,653 shares, 6.1%).

• ·Record date for voting eligibility: March 26, 2026.
• ·Meeting location: 100 Jericho Quadrangle, Suite 100, Jericho, New York 11753.
• ·Conference call access for remote listening: 800-715-9871, conference code 5386343.
• ·2025 Annual Report on Form 10-K available at http://www.astproxyportal.com/ast/21569.

30-04-2026

Ategrity Specialty Insurance Company Holdings (ASIC) filed Definitive Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. This filing supplements prior proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. No financial data, proposals, or operational updates are detailed in the provided filing header.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Filed by the Registrant

30-04-2026

Pacira BioSciences reported Q1 2026 total revenue of $177.4 million, up 5% YoY from $168.9 million, driven by EXPAREL sales of $143.3 million (+5%, with 7% volume growth), ZILRETTA at $26.8 million (+15%), and iovera° at $6.2 million (+21%); however, bupivacaine licensee sales fell to $1.2 million from $2.6 million, operating expenses rose 2% to $170.5 million, GAAP net income declined to $2.9 million from $4.8 million, and adjusted EBITDA dropped to $40.2 million from $44.1 million. The company completed enrollment in the Phase 3 ZILRETTA shoulder osteoarthritis study, on track for year-end topline results, and repurchased 2.2 million shares for $50.0 million.

• ·Reiterated 2026 guidance: EXPAREL net sales $600M-$620M; total revenue $745M-$770M; non-GAAP gross margin 77%-79%; non-GAAP R&D $105M-$115M; non-GAAP SG&A $320M-$340M; stock-based compensation $54M-$62M.
• ·R&D expenses $28.1M in Q1 2026 vs $25.3M in Q1 2025.
• ·SG&A expenses $93.9M in Q1 2026 vs $86.8M in Q1 2025.
• ·$100.0M remaining on share repurchase authorization, expires Dec 31, 2026.
• ·Phase 3 ZILRETTA shoulder OA study topline results expected by end of 2026.
• ·Upcoming readouts: Part A Phase 2 PCRX-201 knee OA; registrational studies for ZILRETTA shoulder OA and iovera° spasticity.

30-04-2026

BayFirst Financial Corp. raised $80 million through a PIPE offering of convertible preferred stock, convertible to approximately 22.9 million common shares at $3.50 per share, and appointed Alfred Rogers as Bank CEO/President replacing retiring Tom Zernick, while naming Kenneth R. Lehman to the boards. However, Q1 2026 results showed a widened net loss of $5.7 million ($1.48 per share) versus $2.5 million in Q4 2025 and $0.3 million in Q1 2025, with loans down 3.5% QoQ to $930.4 million and 14.2% YoY, deposits down 8.3% QoQ to $1.09 billion, and NIM contracting 16 bps QoQ to 3.42%. The capital raise is expected to strengthen proforma capital ratios, including Tier 1 leverage to 10.02%, amid plans to resume preferred dividends and develop an Asset Resolution Plan.

• ·Noninterest income $0.9M in Q1 2026 vs negative $0.1M in Q4 2025 (increase) but down from $8.8M in Q1 2025 due to lower gains on govt guaranteed loan sales.
• ·Noninterest expense $14.9M in Q1 2026, up from $11.9M in Q4 2025 but down from $15.8M in Q1 2025.
• ·Allowance for credit losses to loans 2.35% at March 31, 2026 (down from 2.42% Dec 31, 2025 but up from 1.61% March 31, 2025).
• ·Bank not well-capitalized at March 31, 2026 but proforma CET1 13.13% and total capital 14.40% post-capital contribution.
• ·Special shareholder meeting July 14, 2026 to approve share increase for PIPE conversion; record date May 12, 2026.

30-04-2026

Peoples Financial Services Corp. reported Q1 2026 net income of $14.7 million ($1.47 per diluted share), a 2% decline from $15.0 million ($1.49) in Q1 2025, driven by a $1.2 million increase in provision for credit losses to $1.4 million due to strong loan growth and a $2.5 million rise in noninterest expense to $29.9 million, partially offset by net interest income growth of $3.4 million to $42.9 million and noninterest income up to $6.9 million. Total loans increased $123.3 million or 12.3% annualized to $4.2 billion from $4.1 billion at December 31, 2025, with net interest margin expanding 17 basis points YoY to 3.67%. ROAA and ROAE declined to 1.15% and 11.26% from 1.22% and 12.70% YoY, while asset quality improved with non-performing assets ratio at 0.29%.

• ·ROAA declined to 1.15% from 1.22% YoY; ROAE to 11.26% from 12.70% YoY
• ·Efficiency ratio worsened to 57.09% from 55.77% YoY but improved from 59.53% in Q4 2025
• ·Non-performing assets ratio improved to 0.29% from 0.59% YoY
• ·Book value per common share $52.50 vs $48.21 YoY; tangible book value $42.29 vs $37.35

30-04-2026

Burke & Herbert Financial Services Corp. filed Definitive Additional Proxy Materials (DEFA14A) on April 30, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required. No specific financial data, proposals, or other substantive details are provided in the document excerpt.

30-04-2026

LPL Financial reported first quarter 2026 net income of $356 million, up 12% YoY from $319 million and 19% QoQ from $301 million, with diluted EPS of $4.43 up 4% YoY and adjusted EPS up 9% YoY to $5.60 on 25% YoY gross profit growth to $1,593 million. Total client assets rose 30% YoY to $2.3 trillion, with advisory assets up 42% to $1.4 trillion representing 59.5% of total assets. However, recruited assets declined 55% YoY to $17 billion, total revenue was flat QoQ at $4.938 billion, commission revenue fell 3% QoQ, and client cash balances decreased $2 billion sequentially to $59 billion.

• ·Leverage ratio was 1.86x.
• ·Commonwealth acquisition: estimated run-rate EBITDA decreased to $410 million; on track for Q4 2026 close with ~90% asset retention.
• ·Mariner Advisor Network acquisition announced: supports 367 advisors managing $31 billion assets; 223 to LPL, 144 to hybrid RIA.
• ·Deployed $62 million for six deals in Q1 under Liquidity & Succession.
• ·Lowered upper end of 2026 Core G&A outlook by $20 million to $2,155-2,190 million.
• ·Resumed share repurchases in April with $125 million planned for Q2.
• ·Declared $0.30 per share dividend payable June 4, 2026.

30-04-2026

Ameriprise Financial Inc. held its 2026 annual shareholder meeting on April 29, 2026, with strong turnout of 86.4% (78,335,494 shares represented out of 90,689,669 outstanding shares entitled to vote as of the March 2, 2026 record date). All eight director nominees were elected with majority support, though Amy DiGeso faced notable opposition (7,076,691 votes against); the appointment of PricewaterhouseCoopers LLP as independent auditors for 2026 was ratified overwhelmingly, and the advisory vote on named executive officer compensation passed. No proposals failed, indicating solid shareholder approval across governance matters.

• ·Director election votes - James M. Cracchiolo: 68,019,068 For, 4,534,672 Against, 280,794 Abstentions
• ·Director election votes - Robert F. Sharpe, Jr.: 67,843,593 For, 4,921,475 Against, 69,466 Abstentions
• ·Director election votes - Dianne Neal Blixt: 68,124,291 For, 4,613,738 Against, 96,505 Abstentions
• ·Director election votes - Amy DiGeso: 65,655,057 For, 7,076,691 Against, 102,786 Abstentions
• ·Director election votes - Christopher J. Williams: 71,018,197 For, 1,672,027 Against, 144,310 Abstentions
• ·Director election votes - Glynis A. Bryan: 72,288,976 For, 448,581 Against, 96,977 Abstentions
• ·Director election votes - Liane J. Pelletier: 72,533,365 For, 201,640 Against, 99,529 Abstentions
• ·Director election votes - Brian T. Shea: 71,226,122 For, 1,506,700 Against, 101,712 Abstentions
• ·Audit ratification votes: 75,820,390 For, 2,449,928 Against, 65,176 Abstentions
• ·Executive compensation advisory vote: 65,673,362 For, 6,847,326 Against, 313,846 Abstentions

30-04-2026

UMB Financial Corp reported strong Q1 2026 results with net income of $261,438 thousand, up 221% YoY from $81,333 thousand, fueled by net interest income growth to $534,366 thousand (+34% YoY) and a lower provision for credit losses of $27,000 thousand versus $86,000 thousand. Noninterest income rose to $204,793 thousand (+23% YoY) while noninterest expense slightly declined to $380,883 thousand. However, total assets decreased QoQ to $72,674,161 thousand from $73,094,090 thousand, deposits fell to $59,980,756 thousand from $60,656,790 thousand, and accumulated other comprehensive loss widened to $(331,350) thousand from $(261,520) thousand.

• ·Basic EPS $3.36 in Q1 2026 vs $1.22 in Q1 2025.
• ·Diluted EPS $3.35 in Q1 2026 vs $1.21 in Q1 2025.
• ·Common dividends $0.43 per share in Q1 2026 vs $0.40 in Q1 2025.
• ·Net cash used in investing activities $1,349,699 thousand in Q1 2026 due to $1,346,054 thousand net increase in loans.
• ·Comprehensive income $191,608 thousand in Q1 2026 vs $161,685 thousand in Q1 2025, impacted by $69,830 thousand other comprehensive loss.

30-04-2026

Henson-Edgewater Management, LLC filed a 13F-HR report disclosing 66 equity holdings totaling $157208857 as of March 31, 2026. Top positions include Apple Inc. COM at $21321347 (84012 shares), Bank of America Corp. COM at $9178358 (188274 shares), Alphabet Inc. Cap Stk Cl C at $8327683 (29030 shares), Amazon.com Inc. COM at $8281440 (39763 shares), and Microsoft Corp. COM at $7064102 (19083 shares). All reported shares are held with sole voting power.

• ·Report filed on April 30, 2026 for period ending March 31, 2026.
• ·Portfolio includes significant allocations to technology (e.g., NVIDIA $4880946, 27987 shares), financials (e.g., JPMorgan Chase & Co $2989254, 10162 shares), and ETFs (e.g., Vanguard Index Fds Total Stk Mkt 922908769 $2657542, 8284 shares).

30-04-2026

At the Peapack-Gladstone Financial Corporation's Annual Meeting of Shareholders on April 29, 2026, all 13 director nominees were elected with strong support, receiving between 12,950,059 and 13,210,072 For votes out of 17,570,625 entitled shares. The advisory vote to approve named executive officer compensation passed with 9,461,722 For votes but saw significant opposition with 4,005,485 Against votes. Shareholders overwhelmingly ratified Crowe LLP as the independent auditor for fiscal 2026, with 15,150,537 For votes and minimal opposition.

• ·Proxy statement filed with SEC on March 16, 2026.
• ·Presentation materials from Annual Meeting furnished as Exhibit 99.1 under Item 7.01 (not filed for liability purposes).
• ·F. Duffield Meyercord received the lowest For votes among directors at 12,950,059.

30-04-2026

Fortune Financial Advisors, LLC filed its 13F-HR on April 30, 2026, disclosing 148 equity positions held as of March 31, 2026, with a total market value of $196,213,953, all under sole discretionary authority. Top holdings by value include Garmin Ltd ($15,233,313), iShares TR MSCI USA Min Vol ($11,785,332), NVIDIA Corporation ($6,926,242), Alphabet Inc Cap Stk Cl A ($5,948,300), and Apple Inc ($5,074,288). No changes from prior periods or other voting authority details are reported in the filing.

• ·Report period end date: March 31, 2026
• ·SEC file number: 028-23326
• ·Investment adviser CRD: 145799
• ·Investment adviser ID: 801-78728
• ·Business address: 11600 College Blvd, Suite 225, Overland Park, KS 66210

30-04-2026

Broadridge Financial Solutions reported total revenues of $1,953.6M for the three months ended March 31, 2026, up 7.9% YoY from $1,811.7M, and $5,256.9M for the nine months, up 9.0% YoY from $4,823.7M, with growth across recurring (up 7.0% Q1), event-driven (up 38% Q1), and distribution revenues. Net earnings rose 13.7% YoY to $276.3M in Q1 and 56.1% to $726.2M for nine months, boosted by a $235.0M digital assets fair value gain. However, cash and cash equivalents fell to $304.8M from $561.5M at June 30, 2025, due to $352.9M treasury stock purchases, net debt repayments, and dividends, while foreign currency translation posted a $46.1M loss in Q1 OCI.

• ·Acquisitions net cash outflow of $121.0M for nine months ended March 31, 2026, down from $193.5M prior year.
• ·Accounts receivable increased to $1,319.3M from $1,077.1M at June 30, 2025.
• ·Treasury stock purchases: 1.7M shares for $355.8M in nine months ended March 31, 2026.
• ·Dividends paid: $330.7M for nine months, or $2.925 per share.
• ·Capital expenditures: $35.1M and software purchases $42.1M for nine months.

30-04-2026

The Federal Home Loan Bank of Cincinnati reported the issuance of Consolidated Bonds for which it is the primary obligor, with total par value of $6.225 billion across eight tranches on trade dates April 27-28, 2026. These include seven variable rate Single Index Floater bonds ranging from $50 million to $1.05 billion and one $125 million fixed rate Bermudan bond with a 3.930% coupon. The bonds have short-term maturities through 2027 and are part of routine funding through capital markets via the Office of Finance.

• ·Bonds are non-callable except for the $125M bond which has Optional Principal Redemption Bermudan style with next call July 28, 2026.
• ·All variable bonds are Non-Callable Single Index Floaters with maturities in 2026.
• ·Consolidated Obligations are joint and several obligations of the 11 Federal Home Loan Banks, backed only by their financial resources, not by the U.S. government.